Tryton bifurcation lesion stent
This article was originally published in The Gray Sheet
Executive Summary
Newton, Mass.-based Tryton Medical enrolls one-third of its 30-patient, three-site European feasibility study for the Side-Branch stent, the firm announces Oct. 10. The balloon-expandable stent is used in conjunction with standard coronary stents to treat bifurcation lesions that split into vessels' side branches. The firm hopes to begin a pivotal trial for a drug-eluting version of the product - likely partnering to use a sirolimus derivative - within a year and a half, according to Tryton Chief Technical Officer Richard Davis. The product could reach the U.S. market as early as 2009, he said. According to Tryton, 540,000 procedures for bifurcation lesions are performed each year, representing 20% of all coronary lesions treated. The firm hopes Side-Branch will fill a gap in treatment options to become a new standard of care for these challenging cases...